In-vitro prostate cancer biomarker detection by directed conjugation of anti-PSCA antibody to super paramagnetic iron oxide nanoparticless

Farahani, Mahboube Shahrabi; Mohsenzadegan, Monireh; Taeb, Jaleh; Farajollahi, Mohammad M

doi:10.47176/mjiri.33.16

Cited by 5 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intensity of the blue color (resolution) was observed to be higher with a smaller size (20 nm in diameter) of dex-SPION than a larger one (100 nm). The color intensity verified the efficient binding of anti-PSCA antibody-dex-SPION (20 nm) on the cell surface with improved imaging and targeting ability than dexSPION [64].…”

Section: Antibody and Polypeptide-based Detectionmentioning

confidence: 74%

See 1 more Smart Citation

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common malignancy in men and the leading cause of death for men all over the world. Early diagnosis is the key to start treatment at an early stage of PCa and to reduce the death toll. Generally, PCa expresses characteristic morphologic features and serum biomarkers; however, early diagnosis is challenging due to its heterogeneity and long-term indolent phase in the early stage. Following positive diagnosis, PCa patients receive conventional treatments including surgery, radiation therapy, androgen deprivation therapy, focal therapy, and chemotherapy to enhance survival time and alleviate PCa-related complications. However, these treatment strategies have both short and long-term side effects, notably impotence, urinary incontinence, erectile dysfunctions, and recurrence of cancer. These limitations warrant the quest for novel PCa theranostic agents with robust diagnostic and therapeutic potentials to lessen the burden of PCa-related suffering. Iron oxide nanoparticles (IONPs) have recently drawn attention for their symmetrical usage in the diagnosis and treatment of several cancer types. Here, we performed a systematic search in four popular online databases (PubMed, Google Scholar, Scopus, and Web of Science) for the articles regarding PCa and IONPs. Published literature confirmed that the surface modification of IONPs with biopolymers and diagnostic biomarkers improved the early diagnosis of PCa, even in the metastatic stage with reliable accuracy and sensitivity. Furthermore, fine-tuning of IONPs with biopolymers, nucleic acids, anticancer drugs, and bioactive compounds can improve the therapeutic efficacy of these anticancer agents against PCa. This review covers the symmetrical use of IONPs in the diagnosis and treatment of PCa, investigates their biocompatibility, and examines their potential as PCa theranostic agents.

show abstract

Section: Antibody and Polypeptide-based Detectionmentioning

confidence: 74%

“…It was essential for clinical staging and marking of invasion area e.g., seminal vesicle, prostate capsule, respectively [62,63]. Farahani et al developed an antibody-binding nanoparticle against PSCA for PCa diagnosis [64]. The major challenge was maintaining the ability of antibodies to bind with antigens.…”

Section: Antibody and Polypeptide-based Detectionmentioning

confidence: 99%

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Finally, the most important marker that appears to have a potential role in the development of prostate cancer is PSCA. As mentioned earlier, PSCA antigen is a cell surface antigen that can be effective for many immunological strategies [ 43 ].…”

Section: Psca Expression and Polymorphisms In Different Cancersmentioning

confidence: 99%

Significance of PSCA as a novel prognostic marker and therapeutic target for cancer

Nayerpour Dizaj,

Doustmihan,

Sadeghzadeh Oskouei

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

One of the contributing factors in the diagnosis and treatment of most cancers is the identification of their surface antigens. Cancer tissues or cells have their specific antigens. Some antigens that are present in many cancers elicit different functions. One of these antigens is the prostate stem cell antigen (PSCA) antigen, which was first identified in the prostate. PSCA is a cell surface protein that has different functions in different tissues. It can play an inhibitory role in cell proliferation as well as a tumor-inducing role. PSCA has several genetic variants involved in cancer susceptibility in some tissues, so identifying the characteristics of this antigen and its relationship with clinical features can provide more information on diagnosis and treatment of patients with cancers. Most studies on the PSCA have focused on prostate cancer. While it is also expressed in other cancers, little attention has been paid to its role as a valuable diagnostic, prognostic, and therapeutic tool in other cancers. PSCA has several genetic variants that seem to play a significant role in cancer susceptibility in some tissues, so identifying the characteristics of this antigen and its relationship and variants with clinical features can be beneficial in concomitant cancer therapy and diagnosis, as theranostic tools. In this study, we will review the alteration of the PSCA expression and its polymorphisms and evaluate its clinical and theranostics significance in various cancers.

show abstract

“…In in vitro studies, overexpression of prostate stem cell antigen (PSCA) was identified in 90% of samples where the ability of mAbs to identify PSCA was significantly increased by the use of conjugate–dextran antibodies with superparamagnetic iron oxide [ 44 ]. As such, the labeled cell produces intense blue color upon binding with anti-PSCA-dextran-superparamagnetic iron oxide [ 45 ]. In non-Hodgkin’s lymphoma (NHL), anti-CD20 polyclonal antibody-radioisotopes/fluorophores conjugated with chitosan has been used for its detection [ 46 ].…”

Section: Current Developmental Status Of Abc In Oncologymentioning

confidence: 99%

Antibody–Biopolymer Conjugates in Oncology: A Review

et al. 2023

View full text Add to dashboard Cite

Cancer is one of the most prevalent diseases and affects a large proportion of the population worldwide. Conventional treatments in the management include chemotherapy, radiotherapy, and surgery. Although being well-accepted, they have many lacunas in the form of severe side effect resulting from lack of targeted delivery. Antibody biopolymer conjugates are a novel method which is an add-on to older methods of immunization. It is used in various diseases and disorders. It ensures the targeted delivery of molecules to increase its efficacy and reduce unwanted effects of the molecule/drug to normal cells. It shows miraculous results in the treatment and management of several cancers even in advanced stages. Herein, we present the chemistry between biopolymer and antibody, their effects on cancer as well as the basic differences between antibody–drug conjugates and antibody–biopolymer conjugates.

show abstract

In-vitro prostate cancer biomarker detection by directed conjugation of anti-PSCA antibody to super paramagnetic iron oxide nanoparticless

Cited by 5 publications

References 27 publications

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

Significance of PSCA as a novel prognostic marker and therapeutic target for cancer

Antibody–Biopolymer Conjugates in Oncology: A Review

Contact Info

Product

Resources

About